Abrdn Life Sciences Investors (NYSE:HQL) Shares Acquired by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC increased its position in Abrdn Life Sciences Investors (NYSE:HQL) by 379.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,860 shares of the company’s stock after purchasing an additional 3,847 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Abrdn Life Sciences Investors were worth $64,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Sanctuary Advisors LLC grew its stake in Abrdn Life Sciences Investors by 11.4% in the third quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock worth $183,000 after purchasing an additional 1,355 shares in the last quarter. BankPlus Trust Department acquired a new position in Abrdn Life Sciences Investors in the fourth quarter worth about $28,000. Janney Montgomery Scott LLC grew its stake in Abrdn Life Sciences Investors by 7.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock worth $1,199,000 after purchasing an additional 6,200 shares in the last quarter. Needham Investment Management LLC grew its stake in Abrdn Life Sciences Investors by 3.2% in the third quarter. Needham Investment Management LLC now owns 352,719 shares of the company’s stock worth $5,319,000 after purchasing an additional 10,904 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC acquired a new position in Abrdn Life Sciences Investors in the fourth quarter worth about $160,000. 32.21% of the stock is currently owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Trading Down 0.8 %

NYSE:HQL opened at $13.07 on Wednesday. Abrdn Life Sciences Investors has a one year low of $12.69 and a one year high of $15.90. The stock has a 50-day simple moving average of $13.65 and a 200 day simple moving average of $14.21.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, February 21st will be paid a $0.47 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.88 dividend on an annualized basis and a yield of 14.38%.

Insider Buying and Selling at Abrdn Life Sciences Investors

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $13.75, for a total value of $502,370.00. Following the completion of the transaction, the insider now directly owns 3,276,181 shares in the company, valued at $45,047,488.75. The trade was a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 108,386 shares of company stock worth $1,511,590 over the last ninety days. Company insiders own 10.06% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.